Inhibition of SENP5 suppresses cell growth and promotes apoptosis in osteosarcoma cells

Wang,Kun; Zhang,Xin‑Chao

doi:10.3892/etm.2014.1644

Inhibition of SENP5 suppresses cell growth and promotes apoptosis in osteosarcoma cells

Authors:
- Kun Wang
- Xin‑Chao Zhang
View Affiliations

Affiliations: Department of Orthopedics, Affiliated Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Published online on: March 28, 2014 https://doi.org/10.3892/etm.2014.1644
Pages: 1691-1695

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SUMOylation is a dynamic and reversible process. Several SUMO‑specific proteases (SENPs) that remove SUMO from substrates have been shown to be amplified in a subset of cancers. SENP5 is required for cell division, as well as maintaining mitochondrial morphology and function. SENP5 has been reported to be predominantly localized to the cytoplasm of oral squamous cell carcinoma (OSCC) and is associated with the differentiation of OSCC. Western blot was used to detect the protein expression of SENP5 in osteosarcoma cells and tissue. Lentivirus-mediated siRNA was used to silence the expression of SENP5. Cell cycle distribution was determined by FACS analysis. The present study showed that SENP5 is overexpressed in osteosarcoma cells. In addition, lentivirus‑mediated small interfering RNA (siRNA) of SENP5 significantly inhibited cell growth and induced apoptosis in osteosarcoma cells. SENP5 inhibition suppressed the growth and colony formation capacity of two osteosarcoma cell lines, U2OS and Saos‑2. Silencing the expression of SENP5 in serum‑starved U2OS and Saos‑2 cells induced an increase in caspase‑3/‑7 activity and a decrease in cyclin B1 expression. These observations indicate that SENP5 is required for cell growth and apoptosis and may therefore be a promising drug target for antiosteosarcoma treatment.

View Figures

View References

1	Jaffe N: Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res. 152:239–262. 2009. View Article : Google Scholar : PubMed/NCBI
2	Geiss-Friedlander R and Melchior F: Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 8:947–956. 2007. View Article : Google Scholar : PubMed/NCBI
3	Müller S, Hoege C, Pyrowolakis G and Jentsch S: SUMO, ubiquitin’s mysterious cousin. Nat Rev Mol Cell Biol. 2:202–210. 2001.
4	Hannoun Z, Greenhough S, Jaffray E, Hay RT and Hay DC: Post-translational modification by SUMO. Toxicology. 278:288–293. 2010. View Article : Google Scholar : PubMed/NCBI
5	Hwang KW, Won TJ, Kim H, Chun HJ, Chun T and Park Y: Characterization of the regulatory roles of the SUMO. Diabetes Metab Res Rev. 27:854–861. 2011. View Article : Google Scholar : PubMed/NCBI
6	Yeh ET: SUMOylation and De-SUMOylation: wrestling with life’s processes. J Biol Chem. 284:8223–8227. 2009.PubMed/NCBI
7	Bawa-Khalfe T and Yeh ET: SUMO Losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer. 1:748–752. 2010. View Article : Google Scholar : PubMed/NCBI
8	Kim JH and Baek SH: Emerging roles of desumoylating enzymes. Biochim Biophys Acta. 1792:155–162. 2009. View Article : Google Scholar : PubMed/NCBI
9	Ding X, Sun J, Wang L, et al: Overexpression of SENP5 in oral squamous cell carcinoma and its association with differentiation. Oncol Rep. 20:1041–1045. 2008.PubMed/NCBI
10	Gong L and Yeh ET: Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem. 281:15869–15877. 2006. View Article : Google Scholar : PubMed/NCBI
11	Zunino R, Braschi E, Xu L and McBride HM: Translocation of SenP5 from the nucleoli to the mitochondria modulates DRP1-dependent fission during mitosis. J Biol Chem. 284:17783–17795. 2009. View Article : Google Scholar : PubMed/NCBI
12	Di Bacco A and Gill G: SUMO-specific proteases and the cell cycle. An essential role for SENP5 in cell proliferation. Cell Cycle. 5:2310–2313. 2006.PubMed/NCBI
13	Di Bacco A, Ouyang J, Lee HY, Catic A, Ploegh H and Gill G: The SUMO-specific protease SENP5 is required for cell division. Mol Cell Biol. 26:4489–4498. 2006.PubMed/NCBI
14	Zunino R, Schauss A, Rippstein P, Andrade-Navarro M and McBride HM: The SUMO protease SENP5 is required to maintain mitochondrial morphology and function. J Cell Sci. 120:1178–1188. 2007. View Article : Google Scholar : PubMed/NCBI
15	Alarcon-Vargas D and Ronai Z: SUMO in cancer - wrestlers wanted. Cancer Biol Ther. 1:237–242. 2002. View Article : Google Scholar : PubMed/NCBI
16	Cheng J, Wang D, Wang Z and Yeh ET: SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol. 24:6021–6028. 2004. View Article : Google Scholar : PubMed/NCBI
17	Shen HJ, Zhu HY, Yang C and Ji F: SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of β-catenin. Asian Pac J Cancer Prev. 13:3583–3587. 2012.PubMed/NCBI
18	Han Y, Huang C, Sun X, et al: SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem. 285:12906–12915. 2010. View Article : Google Scholar : PubMed/NCBI
19	Qian J, Luo Y, Gu X and Wang X: Inhibition of SENP6-induced radiosensitization of human hepatocellular carcinoma cells by blocking radiation-induced NF-κB activation. Cancer Biother Radiopharm. 28:196–200. 2013.PubMed/NCBI